19. August 2026

Vaderis Therapeutics, a Swiss clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, has completed a USD 152 million Series B financing and initiated HEROIC, the company’s global Phase 3 clinical study evaluating engasertib (VAD044) in patients with hereditary hemorrhagic telangiectasia (HHT). Together, these milestones mark a significant step forward in the development of engasertib, an investigational oral allosteric AKT inhibitor. Engasertib is positioned to become the first approved therapy specifically developed for people living with HHT, a rare genetic vascular disorder that currently has no approved treatment options worldwide.

The Series B financing was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia. The proceeds from the financing are expected to fund the company’s planned operations through regulatory submissions and potential U.S. regulatory approval.

Walder Wyss has advised Vaderis Therapeutics on all Swiss aspects of this transaction. The team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) ,Marion Bähler (Partner, Corporate/M&A and Venture Capital), Letizia Schlegel (Senior Associate, Corporate/M&A and Venture Capital), Karina Tschon (Managing Associate, Corporate/M&A and Venture Capital), Oerjan Wickart (Associate, Corporate/M&A and Venture Capital) and Dimitrios Berger (Managing Associate, Corporate/M&A).